Ping An Biomedical (MJID) granted 180-day Nasdaq extension to fix sub-$1 bid

Rhea-AI Filing Summary

Ping An Biomedical Co., Ltd. has received an additional 180-day period from Nasdaq to regain compliance with its minimum bid price requirement. The company’s shares have been trading below the required $1 per share, breaching Nasdaq Listing Rule 5550(a)(2).

The new deadline to restore the bid price to at least $1 for 10 consecutive business days is November 23, 2026. Nasdaq granted the extension because the company meets other Capital Market listing standards, and the company indicated it may use a reverse stock split if needed.

The company is evaluating options and intends to regain compliance, but it cautions there is no assurance it will satisfy Nasdaq’s continued listing requirements.

Positive

• None.

Negative

• Ongoing Nasdaq bid-price deficiency and delisting risk: The company has not yet regained compliance with the $1 minimum bid price and warns there is no assurance it will meet Nasdaq’s continued listing requirements by the new November 23, 2026 deadline.

Insights

Equity Markets & Listing Standards Analyst

Nasdaq granted more time, but delisting risk remains.

Ping An Biomedical has secured an extra 180 calendar days, until November 23, 2026, to restore its share price to at least $1 under Nasdaq Listing Rule 5550(a)(2). This indicates it still meets other Capital Market listing criteria such as market value of publicly held shares.

The company signaled it may conduct a reverse stock split to boost the bid price if necessary. Such actions can mechanically lift the share price but do not change underlying business performance. The company also notes there is no assurance it will ultimately achieve compliance.

If the stock trades at or above $1 for at least 10 consecutive business days before the deadline, Nasdaq will confirm compliance and close the matter. Otherwise, investors face the possibility of delisting, which could affect trading liquidity and access to U.S. capital markets.

Key Figures

Minimum bid price requirement: $1 per share Additional compliance period: 180 calendar days New compliance deadline: November 23, 2026 +2 more

5 metrics

Minimum bid price requirement $1 per share Nasdaq Listing Rule 5550(a)(2) continued listing standard

Additional compliance period 180 calendar days Extension granted by Nasdaq to regain bid-price compliance

New compliance deadline November 23, 2026 Last day to restore $1 bid for 10 consecutive business days

Consecutive trading days needed 10 business days Period the bid must be at least $1 to regain compliance

Initial non-compliance period October 10–November 20, 2025 Period when closing bid was below $1, triggering deficiency notice

Key Terms

Nasdaq Listing Rules 5550(a)(2), minimum bid price, market value of publicly held shares, reverse stock split, +2 more

6 terms

Nasdaq Listing Rules 5550(a)(2) regulatory

"the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share"

Nasdaq Listing Rule 5550(a)(2) is a Nasdaq Capital Market standard that sets a minimum share-price requirement companies must meet to list their common stock on that market. Think of it as a minimum entrance score for a club: if a stock trades below the required price, the company can face warnings or removal, which matters to investors because it affects liquidity, tradability and perceptions of company stability.

minimum bid price financial

"to maintain a minimum bid price of $1 per share"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

market value of publicly held shares financial

"based on the Company meeting the continued listing requirement for market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

reverse stock split financial

"its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

continued listing requirement regulatory

"the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement"

Rules a stock exchange sets that a publicly traded company must follow to keep its shares listed, such as minimum share price, market value, shareholder equity, and timely financial reporting. These rules matter to investors because failing them can lead to removal from the exchange, which can make shares harder to buy or sell and often lowers their value — like a club with membership requirements where losing eligibility restricts access and signals trouble.

Capital Market financial

"requirements for initial listing on the Capital Market with the exception of the bid price requirement"

A capital market is the system and places where businesses, governments and other organizations raise long-term money by selling stocks and bonds, and where investors buy and sell those securities. Like a town marketplace where sellers raise funds and buyers choose what to back, capital markets determine how easily organizations get financing, the cost of that financing, and the potential returns and liquidity investors can expect—key drivers of company growth and share prices.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 27, 2026

Commission File Number: 001-42155

Ping An Biomedical Co., Ltd.

(Registrant’s Name)

22/F, China United Plaza, 1002-1008, Tai Nan West Street,

Cheung Sha Wan, Kowloon, Hong Kong

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

It was previously disclosed that on November 24, 2025, that Ping An Biomedical Co., Ltd. (the Company) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

The Company received a letter from Nasdaq on May 26, 2026, noting that while the Company’s listed security has not regained compliance with the minimum $1 bid price per share requirement, Staff has determined that the Company is eligible for an additional 180 calendar day period, or until November 23, 2026, to regain compliance. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company’s security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PING AN BIOMEDICAL CO., LTD.
Date: May 27, 2026	By:	/s/ Pijun Liu
	Name:	Pijun Liu
	Title:	Chairperson of the Board of Directors

2

FAQ

What Nasdaq compliance issue does Ping An Biomedical (MJID) face?

Ping An Biomedical faces a Nasdaq deficiency because its share price stayed below the required $1 minimum bid under Listing Rule 5550(a)(2). This rule is a key continued listing standard for companies on the Nasdaq Capital Market.

How much extra time did Ping An Biomedical (MJID) get from Nasdaq to regain compliance?

Nasdaq granted Ping An Biomedical an additional 180 calendar days, until November 23, 2026, to restore its share price to at least $1. The company previously failed to meet this requirement over an earlier monitoring period.

What must Ping An Biomedical (MJID) do to regain Nasdaq bid-price compliance?

To regain compliance, Ping An Biomedical’s closing bid price must be at least $1 per share for a minimum of 10 consecutive business days. If this occurs before November 23, 2026, Nasdaq will issue written confirmation that the company once again meets the requirement.

Why did Nasdaq allow Ping An Biomedical (MJID) more time to comply?

Nasdaq extended Ping An Biomedical’s deadline because it meets other Capital Market initial listing requirements, including market value of publicly held shares. The company also notified Nasdaq of its intention to cure the bid-price deficiency, potentially through a reverse stock split if needed.

What options is Ping An Biomedical (MJID) considering to fix its Nasdaq deficiency?

The company is evaluating options to lift its share price and stated it may effect a reverse stock split if necessary. A reverse split consolidates shares into fewer units, raising the per-share price without changing overall market capitalization.

Could Ping An Biomedical (MJID) still be delisted from Nasdaq?

Yes. Ping An Biomedical cautions there is no assurance it will regain compliance with Nasdaq’s continued listing requirements. If it fails to maintain a bid price of at least $1 for 10 consecutive business days by November 23, 2026, delisting proceedings could follow.